Publication

Article

Evidence-Based Oncology
February 2015
Volume 21
Issue SP3

FDA Approves Palbociclib for Metastatic Breast Cancer

Author(s):

The FDA has granted an accelerated approval to palbociclib (Ibrance) as a frontline treatment for postmenopausal women with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, based on findings from the phase 2 PALOMA-1 trial.

In the open-label phase 2 study, treatment with letrozole plus the novel CDK 4/6 inhibitor palbociclib reduced the risk of disease progression by 51% compared with letrozole alone. The median progression-free survival (PFS) with palbociclib was 20.2 months versus 10.2 months for letrozole alone (Hazard ratio [HR] = 0.488; P = .0004).

Palbociclib was approved under the FDA’s Breakthrough Therapy designation and priority review program, which provides an expedited approval process for treatments that provide a substantial benefit over current options. The FDA was not scheduled to make a decision on the drug’s application until April 2015. “The addition of palbociclib to letrozole provides a novel treatment option to women diagnosed with metastatic breast cancer,” Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said in a statement. “The FDA is committed to expediting marketing approval of cancer drugs through our accelerated approval regulations.”

To read the article, visit OncLive.

Related Videos
Jessica K. Paulus, ScD, Ontada
Jessica K. Paulus, ScD, Ontada
Michael A. Choti, MD, MBA
Sindhuja Kadambi, MD, MS
Matthew Callister, MD
mily Touloukian, DO, medical oncologist, practice president, and managing partner at Coastal Cancer Center
Neal Shore, MD, FACS, an expert on bladder cancer
Neal Shore, MD, FACS, an expert on bladder cancer
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Related Content
CH LogoCenter for Biosimilars Logo